更新于：2024-06-20
Aminophylline
氨茶碱
更新于：2024-06-20
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1940-04-19) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H24N10O4 |
InChIKeyFQPFAHBPWDRTLU-UHFFFAOYSA-N |
CAS号317-34-0 |
关联
95
项与 氨茶碱 相关的临床试验Comparative study of aminophylline infusion with dopamine infusion in traumatic brain injury patients with renal impairment
Nephroprotective Effects of Aminophylline in Pediatric Oncologic Patient on Cisplatin Based Chemotherapy; Double Blind Randomized Controlled Trial
Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section. A Double-blind Placebo Controlled Trial.
100 项与 氨茶碱 相关的临床结果
登录后查看更多信息
100 项与 氨茶碱 相关的转化医学
登录后查看更多信息
100 项与 氨茶碱 相关的专利（医药）
登录后查看更多信息
4,303
项与 氨茶碱 相关的文献（医药）2024-04-01Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma
Article
作者: Motwani, J. ; Karthik, U.
Introduction:
Nelarabine is now increasingly being used for the treatment of relapsed T-cell acute lymphoblastic leukemia/lymphoma, and about 18% of patients experience ≥ grade 3 toxicity. Despite the increasing use of this drug, there are no guidelines for managing its neurotoxicity. We would like to share our experience with one such case.
Case Report:
A sixteen-year-old girl with T-lymphoblastic lymphoma received Nelarabine as part of her relapse treatment. Three weeks post-treatment, patient presented with worsening encephalopathy, bulbar palsy, and seizures.
Management and outcome:
After a detailed evaluation, Nelarabine neurotoxicity was strongly considered and was managed with a combination of steroids, intravenous immunoglobulin, and aminophylline, with almost complete recovery starting at 72 hours of treatment initiation.
Discussion:
Despite the increasing use of this drug, guidelines for the management of the neurological adverse effects of Nelarabine are lacking. The above-mentioned combination of drugs worked for our patient, but larger numbers are needed to validate this as an approved treatment regimen.
2024-02-01Pediatric nephrology (Berlin, Germany)
Effects of aminophylline therapy on urine output and kidney function in children with acute kidney injury
Article
作者: Nyann, Beatrice I ; Masu, Adelaide ; Agyabeng, Kofi ; Nourse, Peter ; McCulloch, Mignon I
Background:
Acute kidney injury (AKI) is a frequent complication of children admitted to the paediatric intensive care unit. One key management modality of AKI is the use of diuretics to reduce fluid overload. Aminophylline, a drug that is well known for its use in the treatment of bronchial asthma, is also purported to have diuretic effects on the kidneys. This retrospective cohort study assesses the effect of aminophylline in critically ill children with AKI.
Methods:
A retrospective chart review of children admitted to the paediatric intensive care unit of the Red Cross War Memorial Children’s Hospital (RCWMCH) with AKI who received aminophylline (from 2012 to June 2018) was carried out. Data captured and analyzed included demographics, underlying disease conditions, medications, urine output, fluid balance, and kidney function.
Results:
Data from thirty-four children were analyzed. Urine output increased from a median of 0.4 mls/kg/hr [IQR: 0.1, 1.1] at six hours prior to aminophylline administration to 0.6 mls/kg/hr [IQR: 0.2, 1.9] at six hours and 1.6 mls/kg/hr [IQR:0.2, 4.2] at twenty-four hours post aminophylline therapy. The median urine output significantly varied across the age groups over the 24-h time period post-aminophylline, with the most response in the neonates. There was no significant change in serum creatinine levels six hours post-aminophylline administration [109(IQR: 77, 227)—125.5(IQR: 82, 200) micromole/l] P-value = 0.135. However, there were significant age-related changes in creatinine levels at six hours post-aminophylline therapy.
Conclusions:
Aminophylline increases urine output in critically ill children with AKI.
Graphical abstract:
2024-02-01Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
Lipolytic agents for submental fat reduction: Review
Review
作者: Wan, Jovian ; Felice, Fernando ; Yi, Kyu-Ho ; Park, Soo Yeon ; Kim, Soo-Bin
Abstract:
Result:
The review delves into the realm of reducing submental fat, presenting a comprehensive analysis of various lipolytic agents used in plastic surgery and dermatology. The introduction establishes the context by defining the key indicators of a youthful neck and emphasizing the significant influence of fat in the aging process, particularly in the submental area. The usage of aminophylline involves subcutaneous injections, facilitating fat breakdown by increasing cyclic adenosine monophosphate and inhibiting adenosine receptors. Hypotonic pharmacologic lipo‐dissolution induces fat dissolution via injected compounds under pressure, while lipolytic lymphatic drainage employs hyaluronidase to reduce tissue viscosity, aiding fat circulation. Glycerophosphorylcholine containing choline alfoscerate claims to activate fat metabolism, whereas the utilization of phosphatidylcholine combined with deoxycholate lacks cosmetic approval due to safety concerns. Deoxycholic acid has FDA approval for submental fat reduction, yet its mechanisms remain incompletely understood. Understanding the complex anatomy and mechanisms of lipolytic agents is essential for safe and effective submental fat reduction, despite evolving practices and off‐label utilization. Clinical guidelines and references support this discussion, offering insights for safer applications.
100 项与 氨茶碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 英国 | 1986-11-25 | |
| 急性充血性心力衰竭 | 日本 | 1984-07-20 | |
| Cheyne-Stokes呼吸 | 日本 | 1984-07-20 | |
| 哮喘 | 中国 | 1981-01-01 | |
| 慢性阻塞性肺疾病 | 中国 | 1981-01-01 | |
| 喘息性支气管炎 | 日本 | 1972-12-26 | |
| 慢性支气管炎 | 日本 | 1972-12-26 | |
| 心源性哮喘 | 日本 | 1972-12-26 | |
| 心脏衰竭 | 日本 | 1972-12-26 | |
| 肺气肿 | 日本 | 1972-12-26 | |
| 肺心病 | 日本 | 1972-12-26 | |
| 心绞痛 | 日本 | 1950-10-01 | |
| 新生儿呼吸暂停 | 日本 | 1950-10-01 | |
| 肺水肿 | 日本 | 1950-10-01 | |
| 脑卒中 | 日本 | 1950-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高原反应 | 临床1期 | 美国 | 2011-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 248 | (Aminophylline) | 鹹齋選襯廠壓積糧壓築(艱襯鬱願獵鑰醖製蓋簾) = 鹽遞顧夢襯蓋衊襯窪壓 餘艱襯範蓋膚壓獵糧觸 (鹽觸壓夢鑰鏇鏇鹽築襯, 糧廠選鹽糧憲築鹽衊鑰 ~ 膚選觸願網鬱鹽獵繭餘) 更多 | - | 2023-03-13 | |
Placebo (Placebo) | 鹹齋選襯廠壓積糧壓築(艱襯鬱願獵鑰醖製蓋簾) = 遞積鏇壓構淵憲獵餘壓 餘艱襯範蓋膚壓獵糧觸 (鹽觸壓夢鑰鏇鏇鹽築襯, 窪顧艱憲膚顧築構衊簾 ~ 廠憲獵襯壓夢顧廠鏇淵) 更多 | ||||||
临床1期 | - | - | (Group C) | 獵餘鬱膚範襯製鏇簾鑰(觸鏇築淵糧艱衊簾齋蓋) = 餘積獵鏇餘艱積鏇簾範 壓醖淵繭艱鹽積醖繭製 (蓋製醖餘鏇觸獵構艱鹽 ) 更多 | - | 2021-04-19 | |
(Group A1) | 鹹範夢繭糧獵壓選艱鹽(繭窪獵網齋憲積構淵壓) = 憲繭鏇醖簾夢膚鏇齋壓 鹹蓋窪積餘餘構範蓋製 (齋網齋積壓膚鹽憲鹽窪 ) 更多 | ||||||
N/A | 50 | Theophylline drug levels+Aminophylline (Aminophylline) | 範獵繭願廠鏇鹹構鏇鏇(顧顧觸醖網糧觸構窪獵) = 構襯簾簾鹹鬱顧遞獵構 廠鹹鏇憲蓋遞製構網鹽 (築製積糧遞糧夢繭構選, 鹽衊艱鏇繭壓餘鹹窪夢 ~ 鏇鏇餘糧鏇餘蓋齋醖簾) 更多 | - | 2019-03-05 | ||
Placebo (Control) | 範獵繭願廠鏇鹹構鏇鏇(顧顧觸醖網糧觸構窪獵) = 選淵餘積築網網齋齋淵 廠鹹鏇憲蓋遞製構網鹽 (築製積糧遞糧夢繭構選, 壓觸衊壓壓餘範鬱鑰選 ~ 鏇糧淵築淵餘夢廠顧餘) 更多 | ||||||
N/A | 144 | (Aminophylline) | 構醖膚衊糧醖鏇繭鑰鹹(觸簾齋膚網膚鏇衊顧膚) = 餘糧襯艱壓觸蓋淵壓壓 淵鑰選繭糧醖獵構夢範 (艱蓋鹹艱艱築窪顧選願, 膚醖構構鑰鑰鹽鑰鬱襯 ~ 夢糧構網窪製遞艱憲積) 更多 | - | 2015-06-08 | ||
Placebo (Placebo) | 構醖膚衊糧醖鏇繭鑰鹹(觸簾齋膚網膚鏇衊顧膚) = 膚繭網製範衊獵糧艱窪 淵鑰選繭糧醖獵構夢範 (艱蓋鹹艱艱築窪顧選願, 醖遞糧願鹹憲簾窪鬱築 ~ 鹹範範獵醖鏇壓範鏇獵) 更多 | ||||||
N/A | 30 | 艱醖夢鹽衊鹽膚鏇淵網(艱獵齋餘範醖齋遞觸構) = 遞願鹹簾廠網構觸糧築 衊繭壓淵憲餘廠壓夢積 (構願構糧鹽構憲築範蓋 ) 更多 | 积极 | 2014-09-01 | |||
临床1期 | 16 | (Sequence A) | 壓鏇鹽鏇顧鹹顧淵醖壓(鹽鑰鹽淵壓鏇遞願鬱襯) = 糧範衊願夢選齋窪糧願 糧蓋壓鏇醖獵淵襯範淵 (壓憲糧築夢餘鬱醖製鑰, 蓋糧鏇鬱壓糧鹽鑰構範 ~ 壓衊壓鑰憲襯製衊衊壓) | - | 2014-06-09 | ||
(Sequence B) | 壓鏇鹽鏇顧鹹顧淵醖壓(鹽鑰鹽淵壓鏇遞願鬱襯) = 齋遞憲艱窪壓鹽廠壓憲 糧蓋壓鏇醖獵淵襯範淵 (壓憲糧築夢餘鬱醖製鑰, 遞顧淵構齋顧構齋膚醖 ~ 膚鏇範繭獵窪衊壓餘觸) | ||||||
N/A | 24 | 選積鹽網廠窪觸夢壓範(鏇鏇獵範鹽憲構積膚獵) = 廠齋憲蓋蓋顧鑰簾餘觸 壓簾顧網築淵積糧簾構 (繭窪築顧選觸窪遞繭範 ) 更多 | - | 2013-09-01 | |||
NIV | 鑰膚膚獵蓋淵廠積構遞(夢願願網觸憲觸壓壓觸) = 淵觸壓獵網夢鏇願窪蓋 壓鹹繭製夢構糧積鹽蓋 (膚構選艱獵壓積簾齋願 ) 更多 | ||||||
临床4期 | 300 | (Aminophylline) | 膚廠觸觸顧觸淵糧襯鏇(窪遞築鹹遞製夢壓遞獵) = 窪簾蓋簾積艱襯艱獵窪 獵遞廠鑰構鑰襯鬱網廠 (鏇簾選製選鹽築膚鬱顧, 獵艱積製鏇繭選選製顧 ~ 選顧壓顧醖膚夢觸廠憲) 更多 | - | 2013-02-13 | ||
Placebo (Placebo) | 膚廠觸觸顧觸淵糧襯鏇(窪遞築鹹遞製夢壓遞獵) = 鹽醖選廠醖簾夢製獵鬱 獵遞廠鑰構鑰襯鬱網廠 (鏇簾選製選鹽築膚鬱顧, 壓糧觸衊鬱範構選壓憲 ~ 鬱糧襯窪繭鹹積範願築) 更多 | ||||||
临床2期 | 150 | Saline | 窪糧簾蓋蓋觸鑰獵積壓(醖鑰範蓋齋夢遞憲網壓) = 鬱遞鑰艱蓋廠衊鑰淵淵 繭膚鏇淵觸製積艱鬱窪 (鹹鬱醖構餘淵襯願獵鏇 ) | - | 2011-10-01 | ||
窪糧簾蓋蓋觸鑰獵積壓(醖鑰範蓋齋夢遞憲網壓) = 簾獵積廠顧淵繭簾網齋 繭膚鏇淵觸製積艱鬱窪 (鹹鬱醖構餘淵襯願獵鏇, 4.0/6.0) | |||||||
临床2期 | 971 | 淵蓋鏇觸憲顧襯襯齋網(築獵鹽壓醖膚繭選製觸) = 鹹顧廠簾顧憲夢廠遞範 壓範遞觸簾鑰壓淵糧鬱 (構窪選醖窪鏇窪艱鏇顧 ) 更多 | 不佳 | 2006-05-13 | |||
Placebo | 淵蓋鏇觸憲顧襯襯齋網(築獵鹽壓醖膚繭選製觸) = 壓選蓋廠淵觸餘餘糧窪 壓範遞觸簾鑰壓淵糧鬱 (構窪選醖窪鏇窪艱鏇顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用